🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

✍️Life is full of suffering and pain, with periods of happiness ✍️Joy is part of life, but more importantly we should think about meaning ✍️Meaning can come with responsibility and hard work, knowing that our work helps patients life for more than ten years with innovation

Day 2 #MayoCancerNT23 kicks off with #BisAb and #CART jeopardy session led by Saurabh Chhabra Are you ready for Talquetamab in the clinic? Saad kenderian Mayo Clinic Comprehensive Cancer Center

Do ptCY recipients develop cGVHD. Of course they do, but Less often (well known), but the phenotype is very different Rare to see skin sclerosis / BOS (in the absence of DLI / Boost) Less severity #gvhd #bmtsm Saurabh Chhabra Sameem Abedin nature.com/articles/s4140…

The FDA released a warning regarding T cell lymphoma (TCL) development in patients treated with CART therapies. While its occurrence seems rare, the report was concerning given its plausibility. How often does this happen? #CART #mmSM #lymSM 1/x fda.gov/vaccines-blood…

According to the most recent FDA data it has happened at a rate of ~81 reported TCL cases per 100,000 patients (22 cases in over 27,000 CAR-T cell therapies administered) treated with BCMA or CD19 CAR-T therapies. 2/x

So we asked ourselves - What is the background rate of TCL in pts with MM or DLBCL? To address this question we used the Komodo Health’s healthcare map to estimate the yearly incidence/prevalence of TCL in pts with MM and DLBCL. Our document below provides all methods details 3/x

In MM, the prevalence of TCL was 0.10% (99/100k pts) with ≥ 5 billable TCL interactions (BTCI), rising to 0.29% (291 per 100k MM pts) with only ≥ 1 BTCI. The incidence of was 0.06% (56 cases per 100k pts) with ≥ 5 BTCI & 0.24% (238 cases per 100k pts) with only ≥ 1 BTCI 4/x

In DLBCL, the prevalence of TCL was 1.14% (1,140/ 100k pts) with ≥ 5 BTCI and 3.32% (3,316 per 100k pts) with ≥ 1 BTCI. The incidence of TCL in DLBCL was 0.62% (623 per 100k pts) and 2.73% (2,732 cases per 100k pts) with ≥ 5 and ≥1 BTCI 5/x

While these data cannot disprove that some TCLs (a rare event) could be caused by CARTs, our data shows that not all TCL occurring in this context should be assumed to be secondary to the CART product 6/x

While the TCL therapy might be the same, proving causality will require molecular genetic investigation of each case. It seems to us there is much more potential benefit than risk regarding TCL. Our paper does not address MDS/AML 7/x

These data is presented in greater detail in this Substack with the primary author being Dr Gurbakhash Kaur and the other authors are Allison Rosenthal, Eloisa Riva and Saurabh Chhabra open.substack.com/pub/rafaelfons… 8/xl #mmSM #lymSM

1/x Much awaited BMT CTN 1506 trial out in Journal of Clinical Oncology establishing gilteritinib as SOC post #alloBMT maintenance in #MRD +ve FLT3-ITD #AML pts in CR1; thanks to a global collaboration funded by Astellas Pharma US NIH NHLBI and National Cancer Institute to BMT CTN tweetorial👇 ascopubs.org/doi/pdf/10.120…

Granular answers will come from SWOG1803 and GMMG-HD7 trials. For disclosure, until proven otherwise I believe this to be a class-effect, not unique to Dara. We don't know the optimal duration for everyone, 2y reasonable guess based on data. Dr. Amrita Krishnan Saurabh Chhabra 9/9

1/x Our simplified approach MCW Cancer Center for outpatient administration of every single commercial CAR-T product Fateeha Furqan #CART #lymsm #mmsm #leusm pubmed.ncbi.nlm.nih.gov/38889435/

Clearly defines risk of CRS and ICANs in the first two weeks. No need to have patients stick around for a month closer to treatment centers and impose driving restrictions - for what? Thanks you Dr Nausheen Ahmed MD Saurabh Chhabra #mmsm

AGAVE 201 out in NEJM. Remarkable efficacy of axatilimab (blocking CSF1R) in chronic #GvHD. I have some phenomenal response on trial. -Look for puffy eyes - Artifact elevation of AST/ALT/amylase/lipase due to inhibition of kupffer cells Saurabh Chhabra nejm.org/doi/abs/10.105…

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy | Blood Cancer Journal nature.com/articles/s4140…

Record time from #ASH24 oral to Blood Cancer Journal publication! Great work by Luciano J Costa et al. MRD-P (≥10x increase by #MMsm NGS) preceded IMWG PD by 10 months despite Tx sometimes being increased as MRD ⬆️ in MASTER. In other settings, MRD-P might lead to PD even earlier!

Optimal MRD-based end point to support response-adapted treatment cessation in NDMM. ⁦Smit Giri MD MHS⁩ ⁦Natalie Callander⁩ ⁦Susan Bal⁩ ⁦Bhagirath Dholaria, MD⁩ ⁦Binod Dhakal⁩ ⁦Saurabh Chhabra⁩ ⁦Kelly Godby⁩ ashpublications.org/blood/article/…

Love this thread!! #mmsm 👌🏾